



Administration of Medicines Standard Operating Procedure

Version:	V2
Name of originator/ author:	
Responsible management group:	Medicines Governance Group
Directorate/team accountable:	Medical

Procedure:	
Approved by:	Joint Partnership Forum
Date approved:	22 February 2024
Fit for purpose according to:	Medicines Governance Group

Date issued:	22/2/24
Date next review due:	02/02/27
Target audience:	Operational staff
Replaces:	V1.00

Equality Analysis Record	
Approved EA included	Dated: 18 December 2023
Finance checkpoint	
Finance Business Support approved – Financial implications understood.	16/01/2024
	Dated:

Document Control

Formal approval:

Final approval by:	Joint Partnership Forum	
Version No. V2	Final	Date: 22/02/2024
Responsible Management Group approval by:	Medicines Governance Group	

Review/comments:

Person/ Committee	Comments	Version	Date
	New SOP	0.01	Feb 2018
	Approved and published	V1.00	19/03/2018
	Reviewed and updated	1.01	01/02/2022
	Transferred into current template, updated header, footer and formatting	1.02	09/02/2022
	Reviewed the original document v2.00 on 21/02/2022. transferred these comments to this updated version	1.03	23/02/2022
	Updated formatting and responsibilities	1.04	13/07/2022
	Removed CD section (separate SOP) and reworded some items, comments removed.	1.05	15/07/2022
Deputy Chief Pharmacist	Pharmacist final review – addition of definitions, amendment of administration processes in line with most recent policy and education section.	1.06	05/12/2023
Deputy Chief Pharmacist	Amendments as per PGD working group feedback – adjustments to 6.1	1.06	27/12/2023
Chief Pharmacist	Reviewed and approved	1.06	02/01/2024
Assistant Company Secretary	EIA inclusion and final edits	1.07	18/01/2024

Circulation:

Records Management Database upload	Date: 22 February 2024
Internal Stakeholders	
External Stakeholders	

Review Due by responsible Management Group:

Period	Every three years or sooner if new legislation, codes of practice or national standards are introduced	Date: 22 February 2027
--------	--	------------------------

Record Information:

Security Access/ Sensitivity	Official – Sensitive
Where Held	Corporate Records Register
Disposal Method and Date	In line with national guidelines

Contents

Document Control	2
1 Scope.....	5
2 Introduction.....	5
3 Procedure.....	6
3.1. Non CD Medicines Administration	6
3.2. Controlled Drug (CD) Administration.....	7
4 Definitions	7
5 Responsibilities	10
6 Education and Training.....	12
7 Audit and Review for CD SOPs	12
8 Associated Trust Documentation	Error! Bookmark not defined.
9 References	13
10 Financial Checkpoint	Error! Bookmark not defined.
11 Equality Analysis.....	14

1 Scope

- 1.1. South East Coast Ambulance Service NHS Foundation Trust (the Trust) is committed to providing high quality patient care.
- 1.2. The purpose of this Standard Operating Procedure (SOP) is to improve the standards in the security, management and administration of medicines in SECAmb.
- 1.3. This procedure is applicable to all clinicians in the Trust and sets out the scope of clinical practice to which clinicians must adhere.

2 Introduction

2.1. Definition of Medicines

- 2.1.1. “Any substance or combination of substances presented for treating or preventing disease in human beings or in animals. Any substance or combination of substances which may be administered to human beings or animals with a view to making a medical diagnosis or to restoring, correcting or modifying physiological functions in human beings or animals is likewise considered a medicinal product.” Council Directive 65/65/EEC.

2.2. Legal framework for the administration of medicines

- 2.2.1. Medicines are administered to a patient in accordance with a prescription, Patient Specific Direction (PSD), Patient Group Direction (PGD), Trust Approved Protocol or other relevant exemptions specified in the Human Medicines Regulations 2012.

2.3. Personnel authorised to administer medicines as per scope of practice

- Paramedic
- Paramedic practitioner (PP)
- Critical Care paramedic (CCP)
- Advanced Technician
- Associated Ambulance Practitioner (AAP)
- Associate practitioner
- Technicians
- Emergency Care Support Worker (ECSW)
- Community first responder (CFR)

3 Procedure

3.1. All Medicines

- 3.1.1. All medication should be administered in accordance with the SECamb Scope of Practice and Clinical Standards policy.
- 3.1.2. For PGD and Trust Protocol medicines, staff must ensure compliance to administer these drugs (e.g. up-to-date competency assessment through Parapass via JRCALC, training etc).
- 3.1.3. Clinicians must know the therapeutic uses of the medicine to be administered, its normal dosage, side effects, precautions and contra-indication.
- 3.1.4. Where possible, clinicians must check any other medication the patient is receiving or has taken recently for contraindication with the medicine to be administered.
- 3.1.5. If there are any risks associated with the handling or administration of a medicine, clinicians must ensure the risks are minimised where possible, and suitable equipment used.
- 3.1.6. Staff should also have completed the necessary training prior to administration of any medicines.
- 3.1.7. Clinicians must check that the patient is not allergic to the medicine before administration.
- 3.1.8. Clinicians must have considered the dosage, weight where appropriate, method of administration, route and timing
- 3.1.9. Clinicians must check the batch number and expiry date of the medicine to be administered to ensure the medicine is in date prior to administration to our patients.
- 3.1.10. Clinicians must receive the patients consent before administration where applicable.
- 3.1.11. Where possible, clinicians must always get a double check on the medication prior to administration to reduce the risk of error.
- 3.1.12. Clinicians must make a clear, accurate and immediate record of all medication administered or refused on the patient clinical record (PCR) or electronic PCR (ePCR)
- 3.1.13. Documentation must include
 - Incident number (CAD number)
 - Patients name address, date of birth

- Record valid, informed consent was given by the patient (where applicable)
- Record reason for refusal (where applicable)
- Contact details of GP (if registered)
- Diagnosis/working diagnosis
- Dose given/ route given by
- Batch number and expiry date of medicines given
- Time of administration
- Advice given to patient
- Signature and name of staff who administered medication
- Details of any adverse reaction and action taken

3.1.14. Where further clarity or information is required, clinicians are encouraged to contact the clinical operation desk, however verbal orders are not permitted within SECamb and the clinician at scene retains full accountability for all medications administered.

3.1.15. Following administration, the patient should be evaluated and assessed for any adverse effects.

3.1.16. All adverse medications events should be reported via the yellow card scheme <https://yellowcard.mhra.gov.uk> and a datix (DIF1) submitted.

3.2. Controlled Drug (CD) Administration

3.2.1. Please refer to the Administration of Controlled Drugs SOP.

4 Definitions

Associate Ambulance Practitioner (AAP)/Technician	A non-registered healthcare worker who predominantly forms part of a two-person crew. They are trained in technical ambulance skills, assessment techniques and emergency medical care.
Administration	To give a medicine either by introduction into the body e.g., orally, by injection or by external application e.g., impregnated dressing
Adverse Drug Reaction (ADR)	An unwanted or harmful reaction which occurs after administration of a drug or drugs and is suspected or known to be due to the drug(s)
CDs	See Controlled Drugs
CDLO	Controlled Drug Liaison Officers. CDLOs are members of the police force.
Community First Responders (CFRs)	Community First Responders (CFRs) are volunteers who respond to local emergency calls and provide lifesaving first aid before an ambulance arrives.

Controlled Drugs (CDs)	Drugs that are controlled under Misuse of Drugs Act 1971 and the Misuse of Drugs Regulations 2001.
Controlled Drugs Accountable Officer (CDAO)	Member of staff responsible for the governance of controlled drugs within the Trust.
Disposal of Old Pharmaceuticals (DOOP)	Pharmaceutical waste containers designed specifically to render pharmaceuticals products unusable and irretrievable.
Emergency Care Support Worker (ECSW)	A non-registered healthcare worker who forms part of a two-person crew to respond to calls. This role is designed to work alongside another clinician.
Emergency Responder (ER)	A non-registered, service-trained volunteer who attend a range of emergency calls alongside ambulance crews.
General Sales List (GSL) medicines	A medicine that can be sold in general retail outlets (such as supermarkets) without the supervision of a pharmacist. These medicines must be intact in original packaging and often have restricted pack sizes e.g., Paracetamol packs containing 16 tablets
Human Medicines Regulations (HMR)	The main legislation covering the manufacture, importation, distribution, advertising, labelling, sale and supply of medical products for human use and pharmacovigilance.
Joint Royal Colleges Ambulance Liaison Committee (JRCALC) Clinical Guidelines	These are established clinical practice guidelines which include medicines commonly used by ambulance services.
Licensed Medicine	Medicine with a Marketing Authorisation, formerly known as a Product Licence and granted by the Medicines and Healthcare Products Regulatory Agency (MHRA).
Medicine	Medicinal Products as defined by the Medicines Act 1968 i.e. a substance administered by mouth, applied to or introduced into the body for the purpose of treating or preventing disease, diagnosing disease or ascertaining the existence, degree or extent of a physiological condition, contraception, inducing anaesthesia, or otherwise preventing or interfering with the normal operation of a physiological function.
Medicines Governance Group (MGG)	The formal group within SECamb that makes decisions and recommendations regarding medicines and their use within SECamb.
“Off-label” use of Medicine	Medicine with a Marketing Authorisation but being used outside the terms of the Summary of Product Characteristics (Data Sheet).

Non-medical Prescriber	Nurses, pharmacists, physiotherapists, podiatrists and community practitioners who have undertaken further professional training in prescribing.
Non-registered staff	SECamb staff who are employed to deliver patient care but are not formally registered with a professional body (e.g. CFRs, ECSWs, TAAPs etc).
Operational Team Leaders (OTLs)	OTLs are registered paramedics with responsibilities for the safe and secure storage, handling and management of medicines including controlled drugs within operational locations (e.g., ambulance stations).
OTLs	See Operational Team Leaders
Parenteral medicines	Medicines which are administered by injecting directly into the body, bypassing the skin and mucous membranes. The common parenteral routes are intramuscular (IM), subcutaneous (SC) and intravenous (IV).
Patient Group Direction (PGD)	A written instruction to enable certain healthcare professionals to supply or administer a medicine to groups of patients that may not be individually identified before presentation for treatment.
Patient Specific Direction (PSD)	A written instruction from an appropriate prescriber for medicines to be supplied or administered to a named patient. This includes instructions on patients' prescription charts.
Pharmacy (P) Medicines	Any medicinal product other than those designated as GSL or POM products. Pharmacy medicines can be sold or supplied from registered pharmacy by or under the supervision of a pharmacist, subject to certain exceptions.
Preparation of medicines for administration	The activities associated with the preparation of the medicine for use. These include the calculation and selection of doses, the withdrawal of volumes from containers, the preparation of injections from vials/ampoules of dry powder and the preparation of complex admixtures.
Prescription-Only-Medicine (POM)	A medicinal product which may only be sold or supplied against the signed prescription of an appropriate prescriber (e.g., doctor, dentist, independent or supplementary prescriber) and some nurses specified in the Prescriptions Only Medicines (Human Use) Order 1997. The exceptions to this are for emergency medicines used for the purpose of saving a life and exemptions to Medicines Act for podiatrists.
PSD	See Patient Specific Direction.
Registered Doctor	A person whose name appears on the List of Registered Medical Practitioners maintained by the General Medical Council.

Registered Nurse	A person whose name appears on the Register maintained by the Nursing and Midwifery Council as a registered nurse.
Registered Paramedic	A person whose name appears on the Paramedic Register maintained by the Health and Care Professions Council.
Registered Pharmacist	A person whose name appears on the pharmacist register maintained by the General Pharmaceutical Council.
Standard Operating Procedures (SOP)	A document that describes in detail, step-by-step, how a task should be carried out. It also describes the responsibilities, including audits, necessary to safely manage and accountably manage any set processes. It is a working document detailing current agreed working practices
Trainee Associate Ambulance Practitioner (TAAP)	An individual undertaking training to become a associate ambulance practitioner (see associate ambulance practitioner for further details).

5 Responsibilities

- 5.1. The **Chief Executive Officer (CEO)** is accountable for Medicines use and governance in the Trust
- 5.2. The **Executive Medical Director** through delegation by the CEO, has overall responsibility for medicines governance system design and overall assurance. The Executive Medical Director has responsibility for the implementation, review, and thus revision where required, of this procedure.
- 5.3. The **Chief Pharmacist** is the professional medicines governance lead for the Trust and is responsible for producing robust systems and processes which comply fully with legislation, national guidance, and regulatory requirements to ensure the safe and effective management and use of medicines throughout the Trust. The Chief Pharmacist supports the Executive Medical Director and Executive Director of Operations providing pharmaceutical professional advice with regards to all medicines related policies, procedures and practices.
- 5.4. The **Executive Director of Operations**, through delegation by the CEO, has overall responsibility for the implementation, operation and local assurance of this policy. The Executive Director of Operations has overall responsibility for holding his/her staff to account for any deviations from this policy and is responsible for the operational compliance of this procedure.
- 5.5. The **Executive Director of Operations, Executive Medical Director and Chief Pharmacist** are responsible for escalating unresolved concerns to the Medicines Governance Group (MGG).

- 5.6. The Executive Director of Operations delegates local responsibilities and accountability for this procedure to the **Associate Directors of Operations, Operational Unit Managers, Operational Managers, Specialist Managers** and where relevant the **Head of Fleet and Logistics**.
- 5.7. The **Associate Directors of Operations, Operational Units Managers, Operational Managers, Specialist Managers** and where relevant the **Head of Fleet and Logistics** delegate their local responsibility and accountability for this policy to their staff including the **Operational Team Leaders (OTLs), Logistics Manager**, and others.
- 5.8. The **Executive Director of Nursing and Quality** has responsibility for matters relating to regulatory compliance, risk management, health and safety relating to this procedure.
- 5.9. **Controlled Drug Accountable Officer** is also the **Executive Medical Director** and is responsible for the safe management and use of Controlled Drugs within the Trust along with co-operating and sharing information relating to concerns about the Trust's use and management under the Controlled Drug (Supervision of Management and Use) Regulations 2013. These responsibilities include keeping records of the investigation of concerns and acting where appropriate.
- 5.10. The **Medicines Safety Officer (MSO)** is also the **Chief Pharmacist**. The MSO supports local medication error reporting and learning. The MSO acts as the main contact for NHS England and Medicines and Healthcare Products Regulatory Agency (MHRA).
- 5.11. The **Medicines Governance Group (MGG)** is responsible, for providing strategic direction for the implementation of medicines management and practice within the Trust The primary objective of MGG is to ensure appropriate clinical and cost effective use of medicines, promoting the highest standards of medicines management and safe practice throughout the Trust, by ensuring that senior managers are aware of issues relating to the use of medicines within the organisation as part of the overall clinical and corporate governance structure.
- 5.12. The role of The **Non-Medical Prescribing (NMP) Group** is to provide overarching multidisciplinary leadership for non-medical prescribing (NMP) within the Trust. In doing so, it manages the process of Trust approval to train as a non-medical prescriber and to prescribe, taking account of service redesigns and improved patient access to medicines. The NMP Group aims to strengthen and monitor the governance issues associated with non-medical prescribing, to determine potential and support existing non-medical prescribers, advise the MGG on matters relating to non-medical prescribing and will report exceptions relating to non-medical prescribing to the MGG.
- 5.13. The **Medical Gas Subgroup** provides assurance to MGG that medical gases are effectively monitored and managed within the Trust.

- 5.14. The **Patient Group Direction (PGD) Approval and Working Group** provides assurance to MGG and ensures the development, review, updates and implementation of PGDs are in line with legislation and national good practice.
- 5.15. The **Medicines Governance Team (MGT)** are responsible for ensuring the safe and efficient procurement of medicines, including controlled drugs to ensure the quality of the product, safe dispensing/packing into medicines pouches through to safe disposal of pharmaceutical waste. The MGT will support the Chief Pharmacists with drug shortages, drug alerts and relevant information relating to medicines is communicated in a timely manner.
- 5.16. **All staff** are responsible for their own professional practice. All staff involved in the prescribing, supply, dispensing, handling, storage, administration and disposal of medicines, including controlled drugs, must receive appropriate training and assessment of competence before commencing their roles. All staff who handle medicines are personally accountable for complying with this policy and relevant standard operation procedures, for reporting any concerns and for the safe handling of all medicines.

6 Education and Training

- 6.1. The individual is required to have successfully completed the required education and training for their role/grade and must be up to date with Trust statutory and mandatory requirements and authorised for administration of medicines by completion of the appropriate PGD quizzes.

7 Audit and Review for CD SOPs

- 7.1. OTLs (or other registered clinicians delegated local managers) must complete Daily, Weekly, Monthly Medicines Security and Storage Audits on the central database to ensure compliance with this SOP.
- 7.2. Deviations from this SOP must be investigated immediately.
- 7.3. Any deviations for controlled drugs that cannot immediately be resolved must be immediately escalated to the Chief Pharmacist and CDAO and a Datix (DIF1) report submitted immediately.
- 7.4. The CDAO with support from the Director of Operations and Chief Pharmacist must report outstanding controlled drugs concerns to the Medicines Governance Group and the local liaison officer (CDLO)
- 7.5. The CDAO with support from the Chief Pharmacist must report outstanding concerns to the CD LIN (local intelligence network) on a quarterly basis.

- 7.6. Patient Group Directions (PGD) administration will be audited in line with annual audit plan and NICE framework for auditing of PGDs.
- 7.7. All procedures have their effectiveness audited by the responsible Management Group at regular intervals, and initially six months after a new policy is approved and disseminated.
- 7.8. Effectiveness will be reviewed using the tools set out in the Trust's Policy and Procedure for the Development and Management of Trust Policies and Procedures (also known as the Policy on Policies).
- 7.9. This document will be reviewed in its entirety every three years or sooner if new legislation, codes of practice or national standards are introduced, or if feedback from employees indicates that the policy is not working effectively.
- 7.10. All changes made to this procedure will go through the governance route for development and approval as set out in the Policy on Policies.

8 References

- 8.1. Human Medicines Regulations 2012.
<http://www.legislation.gov.uk/ukxi/2012/1916/contents/made>
- 8.2. Nursing and Midwifery Council, Standards for Medicines Management
<https://www.nmc.org.uk/globalassets/sitedocuments/standards/nmc-standards-for-medicines-management>.
- 8.3. NICE guidance, Patient Group Directions, Medicines practice guideline (MPG2GD) March 2017
<https://www.nice.org.uk/guidance/mpg2/chapter/recommendations>
- 8.4. Security standards and guidance for the management and control of controlled drugs in the ambulance sector. National Ambulance Service Medical Directors March 2017
- 8.5. Controlled Drugs (Supervision of Management and Use) Regulations 2013 (SI (2013/373))
- 8.6. Misuse of Drugs Act 1971, 2001 Regulations
- 8.7. Harold Shipman Inquiry Fourth Report - The Regulation of Controlled Drugs in the Community 2004
- 8.8. Safer Management of Controlled Drugs: Guidance on Standard Operating Procedures for Controlled Drugs DOH 2007
- 8.9. Safer Management of Controlled Drugs – Annual Report CQC 2020
- 8.10. Controlled Drugs (supervision and management and use) Regulations 2013 Department of Health

9 Equality Analysis

- 9.1. The Trust believes in fairness and equality, and values diversity in its role as both a provider of services and as an employer. The Trust aims to provide accessible services that respect the needs of each individual and exclude no-one. It is committed to comply with the Human Rights Act and to meeting the Equality Act 2010, which identifies the following nine protected characteristics: Age, Disability, Race, Religion and Belief, Gender Reassignment, Sexual Orientation, Sex, Marriage and Civil Partnership and Pregnancy and Maternity.
- 9.2. Compliance with the Public Sector Equality Duty: If a contractor carries out functions of a public nature then for the duration of the contract, the contractor or supplier would itself be considered a public authority and have the duty to comply with the equalities duties when carrying out those functions.

Equality Impact Assessment (EIA) template (refer to guidance)

What piece of work does this relate to: Administration of Medicines SOP

Lead author:

Pharmacist

Role:

Clinical Pharmacist and Chief

1. Is this a:

- Change to an existing strategy (long term plan of action), policy or procedure ☒
- **Change to a service or function (actions or activities)** ☐
- A new strategy or policy/procedure/business case/ ops bulletin etc. ☐
- A new service or function ☐
- Project which requires approval at Board or Working group ☐

2. Who will be impacted by this work? Tick all that apply.

Patients <input type="checkbox"/>	Student/learners <input type="checkbox"/>	Volunteers <input type="checkbox"/>	External Partners (please specify below) <input type="checkbox"/>
Carers <input type="checkbox"/>	Trade unions <input type="checkbox"/>		Click or tap here to enter text.
Staff <input checked="" type="checkbox"/>	Suppliers <input type="checkbox"/>		Other (including a particular geographical area, describe below) <input type="checkbox"/>
			Click or tap here to enter text.

3. Summarise the work being assessed. Describe current status followed by any changes that stakeholders would experience.

Review and update of existing SOP

4. Checklist

All the Trust's policies, programmes, strategies, services and major developments affect patients, carers, service users, employees and the wider community. These will have a greater or lesser relevance to equality, diversity and inclusion.

The following questions will help you to identify how relevant your proposals are.

When considering these questions think about age, carers, disability, gender reassignment, race, religion or belief, sex, sexual orientation, pregnancy and maternity and any other relevant characteristics (for example socio-economic status, social class, income, unemployment, residential location or family background and education or skills levels).

Make notes to assist with the completion of the EIA.

Questions	Yes	No
Is there potential for/ indication of or evidence that the proposed change will affect different population groups differently (including possibly discriminating against certain groups)?	<input type="checkbox"/>	<input checked="" type="checkbox"/>
Have there been or are there likely to be any public concerns (including media, academic, voluntary or sector specific interest) about the change?	<input type="checkbox"/>	<input checked="" type="checkbox"/>
Could the proposal affect how our services, commissioning or procurement activities are organised, provided, located and by whom?	<input type="checkbox"/>	<input checked="" type="checkbox"/>
Could the proposal affect our workforce or employment practices?	<input type="checkbox"/>	<input checked="" type="checkbox"/>
Is there potential for or evidence that the proposed change will not promote equality of opportunity or promote good relations between different groups?	<input type="checkbox"/>	<input checked="" type="checkbox"/>
If yes to any of the above , please add information in the notes		

5. Equality Impact Assessment

5.1. Key stakeholders

A key principle for completing Equality impact assessment is that they should not be done in isolation. Consultation with affected groups and stakeholders needs to be built in from the start, to enrich the assessment and develop relevant mitigation. Detail here who you have involved with completing this EIA.

Name / Group	Organisation	Role on assessment team e.g., service user, manager of service, specialist (which area)
[REDACTED] / Medicines	SECAmb	

5.2. Who may be positively or negatively affected by this activity?

Protected characteristics (Equality Act 2010) In addition, consider the following vulnerable groups:

- | | | |
|---|---|---|
| Age <input type="checkbox"/> | Armed forces <input type="checkbox"/> | Socioeconomic disadvantage <input type="checkbox"/> |
| Disability <input type="checkbox"/> | Carers <input type="checkbox"/> | People with addiction or substance misuse problems <input type="checkbox"/> |
| Race <input type="checkbox"/> | Digital exclusion <input type="checkbox"/> | People on probation <input type="checkbox"/> |
| Gender reassignment <input type="checkbox"/> | Domestic abuse <input type="checkbox"/> | Prison population <input type="checkbox"/> |
| Marriage & civil partnership <input type="checkbox"/> | Education (literacy) areas <input type="checkbox"/> | Undocumented migrant, refugees, asylum seekers <input type="checkbox"/> |
| Pregnancy & maternity <input type="checkbox"/> | Homeless <input type="checkbox"/> | Sex workers <input type="checkbox"/> |
| Religion & beliefs (including no belief) <input type="checkbox"/> | Looked after children <input type="checkbox"/> | Other (please specify below) <input type="checkbox"/> |
| Sex (male or female) <input type="checkbox"/> | Rural areas <input type="checkbox"/> | |
| Sexual orientation <input type="checkbox"/> | Urban areas <input type="checkbox"/> | |

5.3. Assessment outcomes – discussion undertaken between [Click or tap to enter a date.](#) and [Click or tap to enter a date.](#)

Protected equality characteristic	Describe here the considerations and concerns in relation to the programme/policy for the selected groups. These may be positive, negative or neutral if there is no impact.	If you have identified any negative impacts, describe here suggested mitigations to inform the actions needed to reduce inequalities.
Age	Neutral	
Disability	Neutral	
Race ¹	Neutral	
Gender reassignment	Neutral	
Marriage & civil partnership	Neutral	
Pregnancy & maternity	Neutral	

¹ An ethnic group or ethnicity is a named social category of people who identify with each other on the basis of shared attributes that distinguish them from other groups such as a common set of traditions, ancestry, language, history, society, culture, nation, religion, or social treatment within their residing area. A useful guide to terminology can be found here: <https://www.lawsociety.org.uk/topics/ethnic-minority-lawyers/a-guide-to-race-and-ethnicity-terminology-and-language>

Administration of Medicines Standard Operating Procedure

Religion & beliefs	Neutral	
Sex	Neutral	
Sexual orientation	Neutral	

Vulnerable groups/existing inequity	Describe here the considerations and concerns in relation to the programme/policy for the selected groups. These may be positive, negative or neutral if there is no impact.	If you have identified any negative impacts, describe here suggested mitigations to inform the actions needed to reduce inequalities.
Armed forces	Neutral	
Carers	Neutral	
Digital exclusion ²	Neutral	

² **Digital Exclusion can be linked to the following key root causes:**

- Connectivity access to the internet – can include financial barriers as well as suitable broadband speeds/connectivity
- Digital Skills the ability to use digital tools such as email, online shopping, digital healthcare - also includes having confidence in online safety, and how to utilise particular services or apps

Vulnerable groups/existing inequity	Describe here the considerations and concerns in relation to the programme/policy for the selected groups. These may be positive, negative or neutral if there is no impact.	If you have identified any negative impacts, describe here suggested mitigations to inform the actions needed to reduce inequalities.
Domestic abuse	Neutral	
Education (literacy)	Neutral	
Homeless	Neutral	
Looked after children	Neutral	
Rural/urban geographies	Neutral	
Socioeconomic disadvantage	Neutral	
People with addiction or substance misuse problems	Neutral	
People on probation	Neutral	

-
- Technology and Accessibility access to appropriate devices to suit their individual needs – includes access to devices suitable for use with a certain disability as well as financial and location barriers
 - Not wanting to use digital platforms simply not wishing to utilise digital services – this could be due to distrust of providers, online security, privacy etc.

Vulnerable groups/existing inequity	Describe here the considerations and concerns in relation to the programme/policy for the selected groups. These may be positive, negative or neutral if there is no impact.	If you have identified any negative impacts, describe here suggested mitigations to inform the actions needed to reduce inequalities.
Prison population	Neutral	
Undocumented migrants, refugees, asylum seekers	Neutral	
Sex workers	Neutral	
Other	Neutral	

5.4 Impact on Human Rights

If a provision or feature of your policy or service potentially unlawfully interferes with a human right then it is negative . If something protects or promote a human right, then it is positive. Human rights and freedoms belong to everyone. They give the legal basis to basic values of fairness, respect, equality, dignity and autonomy. They provide a set of minimum legal standards for all public bodies, including the NHS. They protect an individual's rights whilst considering the rights of other people and wider society.

Human Rights	Describe here the considerations and concerns in relation to the programme/policy for the selected groups. These may be positive, negative or neutral if there is no impact.	If you have identified any negative impacts, describe here suggested mitigations to inform the actions needed to reduce inequalities.
A2. Right to life (e.g. Pain relief, DNAR, competency, suicide prevention)	Neutral	
A3. Prohibition of torture, inhuman or degrading treatment (e.g., Service Users unable to consent)	Neutral	
A4. Prohibition of slavery and forced labour (e.g., Safeguarding vulnerable patients' policies)	Neutral	
A5. Right to liberty and security (e.g., Deprivation of liberty protocols, security policy)	Neutral	

Human Rights	Describe here the considerations and concerns in relation to the programme/policy for the selected groups. These may be positive, negative or neutral if there is no impact.	If you have identified any negative impacts, describe here suggested mitigations to inform the actions needed to reduce inequalities.
A6&7. Rights to a fair trial; and no punishment without law (e.g., MHA Tribunals)	Neutral	
A8. Right to respect for private and family life, home and correspondence (e.g., Confidentiality, access to family etc)	Neutral	
A9. Freedom of thought, conscience and religion (e.g., Animal-derived medicines/sacred space)	Neutral	
A10. Freedom of expression (e.g., Patient information or whistle-blowing policies)	Neutral	
A11. Freedom of assembly and association (e.g., Trade union recognition)	Neutral	
A12. Right to marry and found a family (e.g., fertility, pregnancy)	Neutral	
P1.A1. Protection of property (e.g., Service User property and belongings)	Neutral	
P1.A2. Right to education (e.g., accessible information)	Neutral	
P1.A3. Right to free elections (e.g., Foundation Trust governors)	Neutral	

6. Action plan and monitoring arrangements

Insert your action plan here (example layout provided). This should be based on mitigations recommended in 6.2. Involve your key stakeholders in monitoring progress against the actions above, and add more rows as required.

ACTIONS & DECISIONS TRACKER
What is being assessed:

What management group will have oversight of these actions (this should be the group which has oversight of the change):					
Item	Initiation Date	Action/Item	Person Actioning	Target Completion Date	Update/Notes
1					
2					
3					
4					

The above actions should be added to the action log for the named management group.

7. Inclusion Working Member for directorate

Based on your assessment, please indicate which course of action you are recommending to the author. You should explain your recommendation in the blank box below.

Outcome No.	Description	Tick
Outcome One	No major change to the proposal required. This EIA has not identified any potential for discrimination or negative impact, and all opportunities to promote equality have been undertaken. Proceed with the programme and review EIA mid-programme.	
Outcome Two	Adjust the proposal to remove barriers identified by the EIA or better advance equality. Are you satisfied that the proposed adjustments would remove the barriers you identified? Proceed with adjustments, amend programme and review EIA mid-programme.	

Outcome Three	<p>Continue the proposal despite potential for negative impact or missed opportunities to advance equality identified. You will need to make sure the EIA clearly sets out the justifications for continuing with it. You need to consider whether there are:</p> <p>Sufficient plans to stop or minimise the negative impact. Consider if risks need adding to the risk register.</p> <p>Mitigating actions for any remaining negative impacts plans to monitor the actual impact.</p> <p>Proceed with programme. Monitor and evaluate. Discuss with responsible management group and Inclusion Team for advice where required.</p>	
Outcome Four	<p>Stop and rethink the service change/proposal when the EIA shows actual or potential unlawful discrimination. Review change/proposal with the responsible management group for this area of work and identify alternative way forward</p>	
<i>Please use the box on the right to explain the rationale for your recommendation:</i>		

8. Governance

Sign off	Inclusion Working Member for directorate	Date:

9. Version Control

Version Number	Purpose/Change	Author	Date
-----------------------	-----------------------	---------------	-------------

Administration of Medicines Standard Operating Procedure

The above provides historical data about each update made to the EIA.

Please include the name of the author, date and notes about changes made – so that you are able to refer back to what changes have been made throughout this iterative process.

Please send an approved copy of this EA to [REDACTED]

10 Financial Checkpoint

- 10.1 This document has been confirmed by Finance to have no unbudgeted financial implications.